Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Dik J. Kwekkeboom, Wouter W. de Herder, Casper H.J. van Eijck, Boen L. Kam, Martijn van Essen, Jaap J.M. Teunissen, Eric P. Krenning
20100201
2010 Mar 1
Semin Nucl Med
Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Semin Nucl Med. 2010 Mar;40(2):78-88, Dik J. Kwekkeboom, Wouter W. de Herder, Casper H.J. van Eijck, Boen L. Kam, Martijn van Essen, Jaap J.M. Teunissen, Eric P. Krenning
Abstract
Abstract
Somatostatin receptor imaging with [111In-DTPA0)octreotide has proven its role in the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors. Treatment with radiolabeled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized, well-differentiated neuroendocrine tumors. Symptomatic improvement may occur with all 111In, 90Y, or 177Lu-labeled somatostatin analogues that have been used for peptide receptor radionuclide therapy. The results...
